[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.205.0.26. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Evidence to Practice
February 2016

Sacubitril-Valsartan for the Treatment of Heart FailureEffectiveness and Value

Author Affiliations
  • 1Institute for Clinical and Economic Review, Boston, Massachusetts
  • 2Center for Health Policy/Center for Primary Care and Outcomes Research, Department of Medicine, Stanford University, Palo Alto, California
JAMA Intern Med. 2016;176(2):249-250. doi:10.1001/jamainternmed.2015.7661

The Institute for Clinical and Economic Review developed an evidence report, including a systematic review of the literature, a cost-effectiveness analysis, and a potential budget impact assessment, to support a public meeting of the California Technology Assessment Forum (CTAF) on October 29, 2015, on sacubitril-valsartan combination therapy (Entresto, Novartis AG) for heart failure (HF).1

First Page Preview View Large
First page PDF preview
First page PDF preview
×